Cargando…

A study on the prevention of hemorrhage and perforation in patients with primary gastric diffuse large‐B cell lymphoma during treatment with immunochemotherapy

BACKGROUND: Stomach hemorrhage and perforation are very severe and common complications in patients with primary gastric diffuse large B‐cell lymphoma (PG‐DLBCL) during treatment with immunochemotherapy. However, no relevant clinical studies have been performed on the prevention of these serious com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Limei, Huang, He, Wang, Zhao, Fang, Xiaojie, Hong, Huangming, Chen, Yungchang, Ren, Quanguang, Yao, Yuyi, Chen, Zegeng, Pan, Fei, Li, Xiaoqian, Chen, Meiting, Lin, Tongyu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067108/ https://www.ncbi.nlm.nih.gov/pubmed/36621835 http://dx.doi.org/10.1002/cam4.5486

Ejemplares similares

Surgery and Chemotherapy versus Chemotherapy Only in Older Persons with Primary Intestinal Diffuse Large B-Cell Lymphoma
por: Zhang, Limei, et al.
Publicado: (2021)

Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma
por: Chen, Meiting, et al.
Publicado: (2021)

Chemotherapy Plus Radiotherapy Versus Chemotherapy Alone for Patients With Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Chen, Zegeng, et al.
Publicado: (2021)

A novel prognostic nomogram for patients with extragastric mucosa‐associated lymphoid tissue lymphoma: A multicenter study
por: Li, Xiaoqian, et al.
Publicado: (2022)

KIF15 is involved in development and progression of Burkitt lymphoma
por: Wang, Zhao, et al.
Publicado: (2021)

Proposed prognostic subgroups and facilitated clinical decision-making for additional locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: a retrospective study based on recursive partitioning analysis
por: Yao, Yuyi, et al.
Publicado: (2023)

Clinical features and treatment outcome of lymphoepithelioma-like carcinoma from multiple primary sites: a population-based, multicentre, real-world study
por: Chen, Meiting, et al.
Publicado: (2022)

Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
por: Huang, Huageng, et al.
Publicado: (2023)

Characteristics of immunotherapy trials for nasopharyngeal carcinoma over a 15-year period
por: Huang, Huageng, et al.
Publicado: (2023)

A New Immunological Prognostic Model Based on Immunohistochemistry for Extranodal Natural Killer/T-Cell Lymphoma Patients After Non-Anthracycline-Based Chemotherapy
por: Lam, Sio Teng, et al.
Publicado: (2020)

An integrated prognostic model for diffuse large B‐cell lymphoma treated with immunochemotherapy
por: Rodríguez, Marta, et al.
Publicado: (2022)

A modified prognostic model in patients with diffuse large B-cell lymphoma treated with immunochemotherapy
por: Zhao, Peiqi, et al.
Publicado: (2021)

Spontaneous perforation of primary gastric diffuse large B‐cell lymphoma
por: Daoud, Rahma, et al.
Publicado: (2023)

Screening of key genes associated with R-CHOP immunochemotherapy and construction of a prognostic risk model in diffuse large B-cell lymphoma
por: Liu, Ran, et al.
Publicado: (2019)

Anemia as a useful biomarker in patients with diffuse large B-cell lymphoma treated with R-CHOP immunochemotherapy
por: Hong, Junshik, et al.
Publicado: (2014)

Association of Occupational Pesticide Exposure With Immunochemotherapy Response and Survival Among Patients With Diffuse Large B-Cell Lymphoma
por: Lamure, Sylvain, et al.
Publicado: (2019)

The impact of sMICA/sMICB on immunochemotherapy outcomes in newly diagnosed diffuse large B-cell lymphoma
por: Yoon, Sang Eun, et al.
Publicado: (2023)

A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma
por: Liu, Yanyan, et al.
Publicado: (2022)

Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
por: Zhu, Jie, et al.
Publicado: (2020)

A prognostic 15-gene model based on differentially expressed genes among metabolic subtypes in diffuse large B-cell lymphoma
por: Hou, Jun, et al.
Publicado: (2023)

Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy
por: Rovira, Jordina, et al.
Publicado: (2014)

Expression IRF/MUM1>25% Predictor to Three-year Survival of Diffuse Large B Cell Lymphoma in the Immunochemotherapy Era
por: Sofo-Hafizovic, Alma, et al.
Publicado: (2016)

Body Composition as a Predictor of Toxicity and Prognosis in Patients with Diffuse Large B-Cell Lymphoma Receiving R-CHOP Immunochemotherapy
por: Guo, Jiaxun, et al.
Publicado: (2021)

Campylobacter fetus spondylodiscitis during immunochemotherapy for non-Hodgkin's lymphoma
por: Cunha, Jéssica Santos, et al.
Publicado: (2021)

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy
por: Runge, John S., et al.
Publicado: (2020)

Treatment of a Frail Older Patient with Diffuse Large B-Cell Lymphoma on Maintenance Dialysis: Attenuated Immunochemotherapy and Adapted Care Plan
por: de Barros Pontes, Luciola, et al.
Publicado: (2013)

Whole-exome analysis reveals novel somatic genomic alterations associated with outcome in immunochemotherapy-treated diffuse large B-cell lymphoma
por: Novak, A J, et al.
Publicado: (2015)

Clinical Characteristics and Risk of Relapse for Patients with Stage I–II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy
por: Mercadal, S, et al.
Publicado: (2013)

The Prognostic Impact of Comorbidities in Patients with De-Novo Diffuse Large B-Cell Lymphoma Treated with R-CHOP Immunochemotherapy in Curative Intent
por: Kocher, Florian, et al.
Publicado: (2020)

P1189: ENDOTHELIAL ACTIVATION AND STRESS INDEX IS AN INDEPENDENT PROGNOSTIC FACTOR OF DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH STANDARD IMMUNOCHEMOTHERAPY
por: Thanhakun, Ronakrit, et al.
Publicado: (2023)

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)
por: Yoon, Dok Hyun, et al.
Publicado: (2017)

The Geriatric Prognostic Index: a clinical prediction model for survival of older diffuse large B-cell lymphoma patients treated with standard immunochemotherapy
por: Isaksen, Kathrine T., et al.
Publicado: (2023)

Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas
por: Yi, Jun Ho
Publicado: (2021)

Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
por: Castellino, Alessia, et al.
Publicado: (2022)

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
por: Mosquera Orgueira, Adrián, et al.
Publicado: (2023)

Gastric perforation secondary to T-cell lymphoma
por: Fernandez-Alberti, Joaquin, et al.
Publicado: (2023)

Evaluation of 4 prognostic indices in follicular lymphoma treated in first line with immunochemotherapy
por: Rodríguez-Sevilla, Juan Jose, et al.
Publicado: (2022)

More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
por: Lucijanic, Marko, et al.
Publicado: (2021)

Current trends of anticancer immunochemotherapy
por: Vacchelli, Erika, et al.
Publicado: (2013)

Primary Gastrointestinal Diffuse Large B-cell Lymphoma Presenting as Ileal Perforation
por: Rumney, Sean, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u16qcei84nm5anmo6ailafn706